Clinoxus s.r.o.

At Clinoxus s.r.o. in Prague, cardiovascular research focuses on atherosclerotic cardiovascular disease, elevated Lp(a), familial hypercholesterolaemia, and hypertension. These studies are designed to assess whether new treatments can lower heart and vascular risk, improve cholesterol control, and help prevent serious events such as stroke or heart attack.

• Testing therapies aimed at reducing major cardiovascular events and improving long-term heart health
• Studying treatments for inherited and high-risk lipid disorders, including elevated LDL-C and Lp(a)
• Evaluating new approaches for hypertension in people with obesity or overweight

This area reflects a strong focus on prevention and risk reduction, with trials centered on whether emerging medicines can improve outcomes for people living with cardiovascular disease or major risk factors.

Research in digestive system diseases at this site is concentrated on ulcerative colitis and Crohn's disease, including moderately to severely active forms of both conditions. The trials are evaluating new therapies that may help achieve remission, ease symptoms, and improve endoscopic signs of inflammation.

• Investigating treatments for ulcerative colitis in adults and adolescents
• Studying therapies for moderately to severely active Crohn's disease
• Assessing whether new options can improve remission and disease control in inflammatory bowel disease

The overall goal is to identify better ways to manage chronic intestinal inflammation and support more durable symptom relief for patients with inflammatory bowel disease.

The immune system diseases portfolio at Clinoxus s.r.o. includes trials in ulcerative colitis and Crohn's disease, both of which involve immune-driven inflammation. These studies are looking at whether new immune-targeted treatments can improve clinical remission and maintain disease control over time.

• Evaluating immune-focused therapies for moderate to severe ulcerative colitis
• Testing new options for Crohn's disease that may help induce and maintain remission
• Exploring improved treatment effectiveness in chronic inflammatory conditions

This research emphasizes better control of immune-mediated inflammation, with attention to both short-term response and longer-term stability.

In nervous system diseases, the site is involved in research on psychosis associated with Alzheimer’s disease. The trial is focused on understanding whether a new therapy can be safe and well tolerated over time while addressing challenging neuropsychiatric symptoms.

• Studying treatment options for psychosis associated with Alzheimer’s disease
• Assessing long-term safety and tolerability of a therapy for neuropsychiatric symptoms
• Supporting research into more effective management of dementia-related behavioral complications

This area combines neurology and psychiatry, with the aim of improving care for patients affected by complex symptoms linked to Alzheimer’s disease.

The site’s respiratory tract diseases activity appears within a broader clinical research profile that also spans cardiometabolic and inflammatory conditions. At Clinoxus s.r.o., this therapeutic area supports studies exploring whether new treatments can improve disease control and overall patient outcomes in breathing-related disorders.

• Researching therapies intended to improve outcomes in respiratory tract diseases
• Supporting broader clinical evaluation of treatment effectiveness across major chronic disease areas
• Contributing to development of better care strategies for patients with ongoing respiratory health needs

Although the trial portfolio here is more visibly centered on cardiovascular and inflammatory disease, this area remains part of the site’s wider clinical research landscape.